ZoBio offers its proprietary TINS technology for ligand screening studies on our own fragment library or the customer’s. TINS is a powerful approach to hit discovery that has been validated on a wide range of pharmaceutically relevant targets.
TINS uses a sample of the target protein and a reference protein that have been immobilized on sepharose based resin. Binding is detected by a reduction in the height of the NMR signals of a compound that specifically binds to the target. The screen is carried out by repeated cycles of fragment application, assaying for binding and fragment removal. TINS is a powerful approach to hit discovery that has been validated on a wide range of targets including epigenetic targets, viral proteins, proteases, kinases, PPI targets, molecular chaperones and membrane proteins including GPCRs and ligand gated ion channels. A typical TINS hit discovery project including a feasibility phase is completed in 1-2 months.